Search Results - "Shao, Michael Y"

STAT1 pathway mediates amplification of metastatic potential and resistance to therapy by Khodarev, Nikolai N, Roach, Paul, Pitroda, Sean P, Golden, Daniel W, Bhayani, Mihir, Shao, Michael Y, Darga, Thomas E, Beveridge, Mara G, Sood, Ravi F, Sutton, Harold G, Beckett, Michael A, Mauceri, Helena J, Posner, Mitchell C, Weichselbaum, Ralph R

“…Traditionally IFN/STAT1 signaling is connected with an anti-viral response and pro-apoptotic tumor-suppressor functions. Emerging functions of a constitutively…”
Get full text

Type IV Hypersensitivity Reaction after Cyanoacrylate Venous Closure by O'Banion, Leigh Ann A., Shao, Michael Y., Ali, Amna, Kochubey, Mariya, Yan, Yueqi, Fallentine, Joshua, Oh, Jae Hak, Patel, Harik R., Agrawal, Nishant, Carmona, Emely, Hager, Eric S., Kiguchi, Misaki M.

“…Nonthermal endovenous closure techniques are routinely utilized to treat superficial axial venous reflux. Cyanoacrylate closure is a safe and effective…”
Get full text

VIEW-VLU observational study of the effect of Varithena on wound healing in the treatment of venous leg ulcers by Shao, Michael Y., Harlin, Stuart, Chan, Beverly, Santangelo, KathyLee, Fukaya, Eri, Stoughton, Julianne, Kolluri, Raghu, Shao, Michael, Kolluri, Raghu, Chan, Beverly, Ferris, Brian, Fukaya, Eri, Gagne, Paul, Harlin, Stuart, Fries, Richard, Hedayati, Nasim, Niazi, Khusrow, Santangelo, KathyLee, Stoughton, Julianne, Vasquez, Michael, Zeig, Steven

“…Chronic venous hypertension, triggered by venous reflux and/or obstruction, leads to skin changes and venous leg ulcers (VLUs). Compression therapy is the…”
Get full text

Race, sex, and socioeconomic disparities affect the clinical stage of patients presenting for treatment of superficial venous disease by Kiguchi, Misaki M., Fallentine, Joshua, Oh, Jae Hak, Cutler, Bianca, Yan, Yueqi, Patel, Harik R., Shao, Michael Y., Agrawal, Nishant, Carmona, Emely, Hager, Eric S., Ali, Amna, Kochubey, Mariya, O'Banion, Leigh Ann

“…Superficial venous disease has a U.S. prevalence of nearly 30%, with advanced disease contributing to a significant healthcare burden. Although the risk…”
Get full text

Local and Systemic Consequences of Large Retroperitoneal Clot Burdens by Loor, Gabriel, Bassiouny, Hisham, Valentin, Carl, Shao, Michael Y., Funaki, Brian, Desai, Tina

“…Background There is a paucity of data regarding the impact of retroperitoneal hematoma (RPH) volumes, as detected by computed tomography (CT) scanning, on…”
Get full text

Systemic delivery of γ134.5.deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity by VEERAPONG, Jula, BICKENBACH, Kai A, SHAO, Michael Y, SMITH, Kerrington D, POSNER, Mitchell C, ROIZMAN, Bernard, WEICHSELBAUM, Ralph R

“…Abstract Δγ134.5 mutant herpes simplex type 1 viruses are under active clinical investigation as oncolytic therapy for cancer. Mitogen-activated protein…”
Get full text

Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application by Smith, Kerrington D, Shao, Michael Y, Posner, Mitchell C, Weichselbaum, Ralph R

“…Oncolytic Herpes simplex virus -1 (HSV-1) mutants based on deletion of the gamma134.5 gene are promising therapies for cancer. Deltagamma134.5 mutant…”
Get more information

Systemic delivery by intravenous injection of gamma-1-34.5-deleted HSV-1 for oncolytic viral therapy by Shao, Michael Y., MD, Veerapong, Jula, MD, Bickenbach, Kai, MD, Smith, Kerrington D., MD, Roizman, Bernard, PhD, Weichselbaum, Ralph R., MD, Posner, Mitchell C., MD, FACS

Get full text

Type IV Hypersensitivity Reaction After Cyanoacrylate Venous Closure by O'Banion, Leigh Ann, Ali, Amna, Kochubey, Mariya, Yan, Yueqi, Fallentine, Joshua, Oh, Jae Hak, Patel, Harik R., Shao, Michael Y., Agrawal, Nishant, Carmona, Emely, Hager, Eric S., Kiguchi, Misaki

Get full text

Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1 by Advani, S J, Markert, J M, Sood, R F, Samuel, S, Gillespie, G Y, Shao, M Y, Roizman, B, Weichselbaum, R R

“…Oncolytic viruses have been combined with standard cancer therapies to increase therapeutic efficacy. Given the sequential activation of herpes viral genes…”
Get full text

Systemic delivery of (gamma1)34.5-deleted herpes simplex virus-1 selectively targets and treats distant human xenograft tumors that express high MEK activity by Veerapong, Jula, Bickenbach, Kai A, Shao, Michael Y, Smith, Kerrington D, Posner, Mitchell C, Roizman, Bernard, Weichselbaum, Ralph R

“…Deltagamma(1)34.5 mutant herpes simplex type 1 viruses are under active clinical investigation as oncolytic therapy for cancer. Mitogen-activated protein…”
Get full text

Systemic Delivery of gamma sub(1)34.5-Deleted Herpes Simplex Virus-1 Selectively Targets and Treats Distant Human Xenograft Tumors That Express High MEK Activity by Veerapong, Jula, Bickenbach, Kai A, Shao, Michael Y, Smith, Kerrington D, Posner, Mitchell C, Roizman, Bernard, Weichselbaum, Ralph R

“…Delta gamma sub(1)34.5 mutant herpes simplex type 1 viruses are under active clinical investigation as oncolytic therapy for cancer. Mitogen-activated protein…”
Get full text